GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
69.48
+1.22 (1.79%)
Jan 17, 2025, 4:00 PM EST - Market closed

Company Description

GeneDx Holdings Corp., a genomics company, provides personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery.

The company accelerate the use of genomics and leverage clinical data to enable precision medicine as the standard of care.

It utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for clinicians and their patients.

The company offers genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening.

GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

GeneDx Holdings Corp.
GeneDx Holdings logo
Country United States
Founded 2017
Industry Health Information Services
Sector Healthcare
Employees 1,000
CEO Katherine Stueland

Contact Details

Address:
North Tower, 6th Floor
Stamford, Connecticut 06902
United States
Phone 888 729 1206
Website genedx.com

Stock Details

Ticker Symbol WGS
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001818331
CUSIP Number 81663L200
ISIN Number US81663L2007
Employer ID 85-1966622
SIC Code 8000

Key Executives

Name Position
Katherine A. Stueland President, Chief Executive Officer and Director
Kevin Feeley CPA Chief Financial Officer
Dr. Bryan M. Dechairo Ph.D. Chief Operating Officer
Eric Olivares Ph.D. Chief Product and Technology Officer
Heidi C. Chen J.D. Chief Legal Officer
Jami Biliboaca Head of People Strategy
Paul Kruszka FACMG, M.D., M.P.H. Chief Medical Officer
Melanie Duquette Chief Growth Officer
Karen Ponchner Head of Operations
Sabrina Dunbar Chief of Staff

Latest SEC Filings

Date Type Title
Jan 13, 2025 8-K Current Report
Jan 7, 2025 144 Filing
Jan 7, 2025 144 Filing
Jan 2, 2025 8-K Current Report
Jan 2, 2025 144 Filing
Jan 2, 2025 144 Filing
Dec 16, 2024 144 Filing
Dec 16, 2024 144 Filing
Dec 9, 2024 144 Filing
Dec 9, 2024 144 Filing